by Sita Bhella, MD, MEd, FRCPC
Immune effector cell-associated neurotoxicity syndrome is a complication of chimeric antigen receptor T-cell therapy. The condition is characterized by neurologic symptoms, such as tremors,...
by Alex Kadhim
Published in the American Journal of Physical Medicine & Rehabilitation, a brief report explores how cancer patients fare in inpatient rehabilitation after receiving chimeric antigen receptor...
by Alex Kadhim
Researchers at the Children's Hospital of Philadelphia have developed a new strategy to improve the effectiveness of GPC2-directed CAR T-cell therapy in neuroblastoma by reprogramming the...
by Alex Kadhim
Researchers at Memorial Sloan Kettering Cancer Center have found the addition of tocilizumab, an interleukin-6 receptor blocker, to standard GVHD prophylaxis modestly reduces inflammation-related...
by Alex Kadhim
Researchers from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) reported that posttransplant cyclophosphamide (PTCy)-based GVHD prophylaxis significantly improves outcomes for...
by Filippo Milano
This spotlight features Filippo Milano, MD, PhD, a physician-scientist at Fred Hutch and ASTCT board member. As the inaugural Endowed Chair in Cord Blood Research, he shares his journey from Rome...